<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04217356</url>
  </required_header>
  <id_info>
    <org_study_id>19-6362</org_study_id>
    <secondary_id>ALLO-BAT</secondary_id>
    <nct_id>NCT04217356</nct_id>
  </id_info>
  <brief_title>Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis</brief_title>
  <acronym>ALLO-BAT</acronym>
  <official_title>A Patient Preferences-Controlled Study of Allogeneic Hematopoietic Cell Transplantation Versus Best Available Non-Transplant Therapies in Patients With High-Risk Myelofibrosis (ALLO-BAT Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to see how effective hematopoietic stem cell&#xD;
      transplantation (HCT) is compared to best available non-transplant therapies (BAT) in&#xD;
      patients with high risk myelofibrosis. This will be done by asking participants to choose the&#xD;
      treatment that they prefer to receive (HCT or BAT) and then comparing the outcomes of the&#xD;
      participants in both treatment groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is currently little information regarding which treatments are best for patients with&#xD;
      myelofibrosis. On one hand, hematopoietic stem cell transplantation (HCT) is potentially&#xD;
      curative treatment but is associated with significant risk of complications related to graft&#xD;
      failure (the new donor cells does not grow properly after the transplant), side effects such&#xD;
      as graft versus host disease (the patient's cells attack the new donor cells), and risk of&#xD;
      infections. Non-transplant therapies such as ruxolitinib provide effective symptom control&#xD;
      for few months to few years, but are not curative in nature. As such, this study will compare&#xD;
      the effectiveness of HCT versus best available non-transplant therapies (BAT) in patients&#xD;
      with high risk myelofibrosis.&#xD;
&#xD;
      This is an observational study, meaning that participants will be followed to assess the&#xD;
      effects of their treatment, but no intervention (treatments) will be given as a part of this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2020</start_date>
  <completion_date type="Anticipated">February 5, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 5, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients allocated to hematopoietic stem cell transplantation (HCT)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients allocated to best available non-transplant therapies (BAT)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival rate of patients who receive hematopoietic stem cell transplantation (HCT)</measure>
    <time_frame>5 years</time_frame>
    <description>Time from study allocation to death or last follow up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival rate of patients who receive best available non-transplant therapies (BAT)</measure>
    <time_frame>5 years</time_frame>
    <description>Time from study allocation to death or last follow up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median change in Patient Global Impression of Change (PGIC) score</measure>
    <time_frame>0 and 36 months</time_frame>
    <description>Range from -3 to 3. Positive number equals increase in quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median change in MPN Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)</measure>
    <time_frame>0 and 36 months</time_frame>
    <description>Range from 0 to 10. Increase equals worsening of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median change in FACT-BMT Questionnaire</measure>
    <time_frame>0 and 36 months</time_frame>
    <description>Range from 1 to 4. Increase equals increase in quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival of patients who receive hematopoietic stem cell transplantation (HCT)</measure>
    <time_frame>5 years</time_frame>
    <description>Time from allocation to study arm to death/acute myeloid leukemia transformation or last follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival of patients who receive best available non-transplant therapies (BAT)</measure>
    <time_frame>5 years</time_frame>
    <description>Time from allocation to study arm to death/acute myeloid leukemia transformation or last follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who receive hematopoietic stem cell transplantation (HCT) in remission (complete and partial)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who receive best available non-transplant therapies (BAT) in remission (complete and partial)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Myelofibrosis</condition>
  <condition>High-Risk Cancer</condition>
  <condition>Bone Marrow Cancer</condition>
  <arm_group>
    <arm_group_label>Hematopoietic stem cell transplant (HCT)</arm_group_label>
    <description>Standard of care hematopoietic stem cell transplant with a matched donor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best available non-transplant therapies (BAT)</arm_group_label>
    <description>Standard of care treatment with a janus kinase (JAK) inhibitor drug called ruxolitinib or treatment with an antimetabolite drug called hydroxyurea.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hematopoietic stem cell transplant</intervention_name>
    <description>Intravenous infusion of hematopoietic stem cells from a donor.</description>
    <arm_group_label>Hematopoietic stem cell transplant (HCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>Ruxolitinib is type of drug called a janus kinase (JAK) inhibitor. Ruxolitinib is taken orally (by mouth).</description>
    <arm_group_label>Best available non-transplant therapies (BAT)</arm_group_label>
    <other_name>JAKAVI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyurea</intervention_name>
    <description>Hydroxyurea is a type of drug called an antimetabolite. Hydroxyurea is taken orally (by mouth).</description>
    <arm_group_label>Best available non-transplant therapies (BAT)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples for future research related to hematological (blood) cancers and their&#xD;
      treatments.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with high-risk myelofibrosis including pre-fibrotic primary myelofibrosis&#xD;
        (pre-fibrotic primary myelofibrosis), overt primary myelofibrosis, post-polycythemia&#xD;
        myelofibrosis or post-essential thrombocythemia myelofibrosis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Recruitment Part:&#xD;
&#xD;
          -  Documented diagnosis of pre-fibrotic primary myelofibrosis (pre-fibrotic PMF), overt&#xD;
             PMF, post-polycythemia MF (PPV-MF) or post-essential thrombocythemia MF (PET-MF)&#xD;
             confirmed by bone marrow biopsy&#xD;
&#xD;
          -  Have been tested or have results available for phenotypic driver mutations&#xD;
             (JAK2/CALR/MPL) and high molecular risk (HMR) mutations using a broad myeloid&#xD;
             malignancies targeted gene panel.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Donor search initiated or patient is agreeable to donor search&#xD;
&#xD;
          -  Meet the definition/criteria for high-risk myelofibrosis&#xD;
&#xD;
        Study Arm Allocation:&#xD;
&#xD;
          -  Grade of fibrosis on bone marrow biopsy available according to World Health&#xD;
             Organization (WHO) criteria&#xD;
&#xD;
          -  Results available for phenotypic driver mutations (JAK2/CALR/MPL) and targeted&#xD;
             sequencing results using a broad myeloid malignancy panel with a minimal requirement&#xD;
             to include results on High molecular risk (HMR) mutations such as&#xD;
             ASXL1/EZH2/IDH1/IDH2/SRSF2/U2AF1/TP53&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Information on donor search and donor type available&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Recruitment Part:&#xD;
&#xD;
          -  Blasts in peripheral blood or bone marrow ≥10%&#xD;
&#xD;
          -  For patients already on ruxolitinib at study entry, and meet the criteria of&#xD;
             ruxolitinib failure&#xD;
&#xD;
          -  Previous history of transformation to blast phase or acute myeloid leukemia&#xD;
&#xD;
          -  Received allogeneic stem cell transplant for myeloproliferative neoplasm&#xD;
&#xD;
          -  Presence of an active uncontrolled infection&#xD;
&#xD;
          -  Myocardial infarction in the preceding 3 months&#xD;
&#xD;
          -  Active hepatitis A, B or C&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) positive&#xD;
&#xD;
          -  History of active malignancy in the previous 2 years, except basal cell carcinoma or&#xD;
             squamous cell carcinoma of skin or stage 0 cervical cancer&#xD;
&#xD;
          -  Any psychiatric illness or social circumstances or significant co-morbid conditions&#xD;
             that will prevent patient from proceeding to allogeneic hematopoietic cell&#xD;
             transplantation.&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
        Study Arm Allocation:&#xD;
&#xD;
          -  Blasts in peripheral blood or bone marrow ≥10%&#xD;
&#xD;
          -  Meet the criteria of ruxolitinib failure&#xD;
&#xD;
          -  Presence of an active uncontrolled infection&#xD;
&#xD;
          -  Myocardial infarction in the preceding 3 months&#xD;
&#xD;
          -  Active hepatitis A, B or C&#xD;
&#xD;
          -  Known HIV positive&#xD;
&#xD;
          -  History of active malignancy in the previous 2 years, except basal cell carcinoma or&#xD;
             squamous cell carcinoma of skin or stage 0 cervical cancer&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Any psychiatric illness or social circumstances or significant co-morbid conditions&#xD;
             that will prevent patient from proceeding to allogeneic hematopoietic cell&#xD;
             transplantation.&#xD;
&#xD;
          -  Time between registration and allocation of study arm &gt;24 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vikas Gupta, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vikas Gupta, M.D.</last_name>
    <phone>416-946-2885</phone>
    <email>vikas.gupta@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Cerquozzi, M.D.</last_name>
      <phone>403-944-5948</phone>
    </contact>
    <investigator>
      <last_name>Sonia Cerquozzi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elena Liew, M.D.</last_name>
      <phone>780-417-1584</phone>
    </contact>
    <investigator>
      <last_name>Elena Liew, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6E1M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lynda Foltz, M.D.</last_name>
      <phone>604-682-2344</phone>
      <phone_ext>64986</phone_ext>
    </contact>
    <investigator>
      <last_name>Lynda Foltz, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nova Scotia Health Authority</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mahmoud Elsawy, M.D.</last_name>
      <phone>902-473-7006</phone>
    </contact>
    <investigator>
      <last_name>Mahmoud Elsawy, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vikas Gupta, M.D.</last_name>
      <phone>416-946-2885</phone>
    </contact>
    <investigator>
      <last_name>Vikas Gupta, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 2, 2020</study_first_submitted>
  <study_first_submitted_qc>January 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2020</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High-Risk Myelofibrosis</keyword>
  <keyword>Stem Cell</keyword>
  <keyword>Transplantation</keyword>
  <keyword>Myelofibrosis</keyword>
  <keyword>Bone marrow cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Marrow Neoplasms</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

